Kymera discusses Phase 1b data for KT-621 in atopic dermatitis on Dec 8 call

Kymera Therapeutics, Inc.

Oral STAT6 degrader KT-621 BroADen Phase 1b results presented; slide deck furnished.
Specific efficacy, safety, and biomarker outcomes not available from provided text.
Conference call hosted by CEO Nello Mainolfi and CMO Jared Gollob.
KT-621 is first-in-class oral STAT6 degrader targeting Th2-driven inflammation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.